FY2025 EPS Estimates for ClearPoint Neuro Raised by B. Riley

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) - Equities researchers at B. Riley lifted their FY2025 earnings per share (EPS) estimates for ClearPoint Neuro in a note issued to investors on Thursday, February 27th. B. Riley analyst K. Bauser now forecasts that the company will earn ($0.58) per share for the year, up from their prior estimate of ($0.59). B. Riley has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for ClearPoint Neuro's current full-year earnings is ($0.66) per share. B. Riley also issued estimates for ClearPoint Neuro's Q4 2025 earnings at ($0.15) EPS.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The firm had revenue of $7.77 million during the quarter, compared to analysts' expectations of $8.23 million.

Separately, Lake Street Capital lifted their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, January 21st.

ClearPoint Neuro Price Performance

Shares of CLPT stock traded down $0.98 during trading hours on Monday, reaching $13.19. 294,782 shares of the company's stock were exchanged, compared to its average volume of 235,981. ClearPoint Neuro has a 1 year low of $5.11 and a 1 year high of $19.22. The company has a market cap of $364.47 million, a P/E ratio of -19.12 and a beta of 1.06. The company's 50 day moving average is $16.47 and its two-hundred day moving average is $13.93.

Remove Ads

Institutional Investors Weigh In On ClearPoint Neuro

A number of institutional investors have recently modified their holdings of the stock. Invesco Ltd. acquired a new stake in shares of ClearPoint Neuro in the 4th quarter worth about $3,814,000. Conway Capital Management Inc. bought a new stake in ClearPoint Neuro during the third quarter worth approximately $1,586,000. Jane Street Group LLC grew its holdings in shares of ClearPoint Neuro by 119.6% in the 4th quarter. Jane Street Group LLC now owns 222,307 shares of the company's stock worth $3,419,000 after acquiring an additional 121,083 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in ClearPoint Neuro during the 4th quarter worth about $1,633,000. Finally, Man Group plc acquired a new position in ClearPoint Neuro in the 4th quarter worth approximately $1,107,000. Institutional investors and hedge funds own 30.08% of the company's stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.